文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

有效抗病毒治疗期间HIV-1 DNA逆转录酶序列中耐药相关突变的动态变化

Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

研究纳入25例既往RNA序列检出拉米夫定/恩曲他曲韦、依曲韦林和/或利匹韦林耐药相关突变的患者,在排除相应耐药类药物的有效方案下病毒学控制至少5年,对细胞相关HIV-1 DNA逆转录酶区行纵向超深度测序与Sanger测序。结果显示72%患者5年内UDS不再检出相关耐药突变,5年后80%(UDS)和88%(Sanger)患者病毒对目标药物敏感。

要点

  • 有效ART且无选择性压力5年内,72%患者UDS不再检出既往耐药相关突变
  • 5年后对目标药物敏感的病毒在UDS为80%、Sanger为88%患者中检出
  • 52%患者检出<50 copies/mL的残余病毒血症,HIV DNA中位数水平保持稳定

核心结论

  • 有效抗病毒治疗且无相应药物选择压力长期病毒学控制后,细胞相关HIV-1 DNA中存档的逆转录酶抑制剂耐药相关突变呈清除趋势,反映某些病毒库中可能存在的残余复制及存档HIV-1 DNA耐药谱的持续演变。

研究设计与样本

  • 研究纳入25例患者,其病史中RNA序列至少检出1个对拉米夫定/恩曲他滨、依曲韦林和/或利匹韦林的耐药相关突变,且在接受排除所有耐药类别药物的方案下病毒学控制至少5年。
  • 对5年随访期间采集的细胞相关HIV-1 DNA样本的逆转录酶区进行纵向超深度测序(UDS)和Sanger测序。

主要发现

  • 72%患者在5年内UDS不再检出携带所分析耐药相关突变的病毒变异株。
  • 5年后对目标药物敏感的病毒在UDS中检出于80%患者,在Sanger测序中检出于88%患者。
  • 52%患者检出<50 copies/mL的残余病毒血症。
  • HIV DNA中位水平保持稳定:基线2.4 vs 5年后2.1 log10 copies/106细胞。

关键数值与推荐

  • 5年内UDS不再检出所分析耐药相关突变者占72%。
  • 5年后检出对目标药物敏感病毒者:UDS 80%,Sanger测序88%。
  • 残余病毒血症<50 copies/mL者占52%。
  • HIV DNA中位水平:基线2.4 vs 5年后2.1 log10 copies/106细胞。

临床怎么用

  • 作者认为,长期病毒学控制且无相应耐药相关突变选择压力后,存档耐药相关突变呈清除趋势,反映某些病毒库中可能存在的残余复制及存档HIV-1 DNA耐药谱的持续演变。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the dynamics of HIV-1 variants archived in cells harbouring drug resistance-associated mutations (DRAMs) to lamivudine/emtricitabine, etravirine and rilpivirine in patients under effective ART free from selective pressure on these DRAMs, in order to assess the possibility of recycling molecules with resistance history. PATIENTS AND METHODS: We studied 25 patients with at least one DRAM to lamivudine/emtricitabine, etravirine and/or rilpivirine identified on an RNA sequence in their history and with virological control for at least 5 years under a regimen excluding all drugs from the resistant class. Longitudinal ultra-deep sequencing (UDS) and Sanger sequencing of the reverse transcriptase region were performed on cell-associated HIV-1 DNA samples taken over the 5 years of follow-up. RESULTS: Viral variants harbouring the analysed DRAMs were no longer detected by UDS over the 5 years in 72% of patients, with viruses susceptible to the molecules of interest found after 5 years in 80% of patients with UDS and in 88% of patients with Sanger. Residual viraemia with <50 copies/mL was detected in 52% of patients. The median HIV DNA level remained stable (2.4 at baseline versus 2.1 log10 copies/106 cells 5 years later). CONCLUSIONS: These results show a clear trend towards clearance of archived DRAMs to reverse transcriptase inhibitors in cell-associated HIV-1 DNA after a long period of virological control, free from therapeutic selective pressure on these DRAMs, reflecting probable residual replication in some reservoirs of the fittest viruses and leading to persistent evolution of the archived HIV-1 DNA resistance profile.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Nouchi A, Nguyen T, Valantin MA, et al. Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART. J Antimicrob Chemother. 2018. PMID: 29846589. doi:10.1093/jac/dky130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。